|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||||||||
| Current assets: | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Short-Term Investments | |||||||||||||||||||
| Tax receivable | |||||||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||||||
| Total current assets | |||||||||||||||||||
| Other assets | |||||||||||||||||||
| Deferred offering costs | |||||||||||||||||||
| Cash and cash equivalents and long term invesrments | |||||||||||||||||||
| Right-of-use assets, net | |||||||||||||||||||
| Property and equipment, net | |||||||||||||||||||
| Total assets | |||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||||||||||
| Current liabilities: | |||||||||||||||||||
| Accounts payable and accrued expenses | |||||||||||||||||||
| Operating lease liability - current | |||||||||||||||||||
| Total current liabilities | |||||||||||||||||||
| Operating lease liability – long term | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| Stockholders’ equity: | |||||||||||||||||||
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 71,608,042 shares issued and 71,535,679 shares outstanding at June 30, 2026 and 53,023,466 shares issued and 52,951,103 shares outstanding at December 31, 2025 | |||||||||||||||||||
| Additional paid-in capital | |||||||||||||||||||
| Accumulated other comprehensive income | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| Treasury stock at cost, 72,363 shares as of December 31, 2024 and 2023 | |||||||||||||||||||
| Total Immix Biopharma, Inc. stockholders’ equity | |||||||||||||||||||
| Non-controlling interests | |||||||||||||||||||
| Treasury stock at cost, 72,363 shares as of June 30, 2026 and December 31, 2025 | |||||||||||||||||||
| Total stockholders’ equity | |||||||||||||||||||
| Total liabilities and stockholders’ equity | |||||||||||||||||||
Loading...
